



## Nanobiotix - Revenue for the second quarter of 2013

Paris, France, July 12, 2013 – NANOBIOTIX (Euronext : NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.

### Income statement

<i>in €</i>	Q2 2013*	H1 2013
<b>Revenue</b>	<b>48,569</b>	<b>95,050</b>
of which :		
<i>License</i>	45,847	93,328
<i>Services</i>	2,722	2,722

*\*over the second quarter of 2012, the company recorded no revenue*

### Activity

As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts to €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.

Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).

### Financial calendar

*Results for the first half of 2013, on August 30, 2013*



**About NANOBIOTIX:** [www.nanobiotix.com/fr](http://www.nanobiotix.com/fr)

Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix's lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP).



## Contacts

### **Nanobiotix**

**Laurent Levy**

*CEO*

+33 (0)1 40 26 07 55

[laurent.levy@nanobiotix.com](mailto:laurent.levy@nanobiotix.com)

### **NewCap.**

*Financial communication  
and investors relations*

**Louis-Victor Delouvrier / Emmanuel Huynh**

+33 (0)1 44 71 98 53

[lvdelouvrier@newcap.fr](mailto:lvdelouvrier@newcap.fr)



### **Yucatan**

*Media relations (France)*

**Annie-Florence Loyer/ Nadège Le Lezec**

+33 (0)1 53 63 27 27 / +33 (0)6 88 20 35 59

[afloyer@yucatan.fr](mailto:afloyer@yucatan.fr)

### **College Hill**

*Media relations (Outside France)*

**Melanie Toyne Sewell / Claire Dickinson /**

**Donia Al Saffar**

+44 (0) 207 457 2020

[nanobiotix@collegehill.com](mailto:nanobiotix@collegehill.com)